| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Feb'12 | Feb'11 |
|---|---|---|---|---|---|---|---|---|---|
Cash Flows From Operating Activities: | |||||||||
Net income (loss) | |||||||||
-146,427 | -102,678 | -59,731 | -47,903 | 117,237 | -110,938 | -34,625 | -30,343 | -14 | -23 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Depreciation and amortization | |||||||||
20,408 | 18,668 | 17,804 | 16,135 | 13,392 | 5,401 | 216 | 124 | - | - |
(Accretion) amortization of discounts/premiums on investments, net | |||||||||
788 | -382 | -1,338 | 1,097 | 398 | 0 | 0 | 0 | 0 | 8 |
Impairment of Retained Interest | |||||||||
15,000 | 0 | 0 | - | - | - | - | - | - | - |
Accretion of notes receivable | |||||||||
0 | 0 | 651 | 1,927 | 1,267 | 0 | 0 | - | - | - |
Accretion of contingent consideration | |||||||||
1,485 | 1,357 | 1,723 | 1,976 | 2,461 | 0 | - | - | - | - |
Amortization of debt discount and issuance costs | |||||||||
9,903 | 3,398 | 656 | 656 | 1,340 | 1,084 | 0 | 0 | - | - |
Realized (gain) loss on marketable securities | |||||||||
- | - | - | - | - | 2,349 | 374 | 0 | - | - |
Gain upon divestiture of Pediatric Priority Review Voucher | |||||||||
- | - | - | - | 140,004 | 0 | - | - | - | - |
Gain upon divestiture of assets to Turing Pharmaceuticals | |||||||||
- | - | - | - | 914 | 0 | - | - | - | - |
Settlement expense | |||||||||
0 | 0 | -2,625 | -5,212 | 0 | -6,018 | 0 | 0 | - | - |
Loss on extinguishment of debt | |||||||||
0 | -17,042 | 0 | 0 | -4,151 | 0 | 0 | - | - | - |
Impairment of Intangible Assets, Finite-lived | |||||||||
25,500 | 0 | 0 | - | 4,710 | 0 | 0 | - | - | - |
Loss on disposal of fixed assets | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Provision for Inventory | |||||||||
1,468 | 2,457 | 609 | 262 | 1,050 | 0 | 0 | - | - | - |
2013 private placement settlement | |||||||||
- | - | - | - | - | - | 0 | 0 | - | - |
Lease liability | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Non-cash financing cost | |||||||||
- | - | - | - | - | 4,708 | 0 | 0 | - | - |
Loss on impairment of cost method purchase | |||||||||
- | - | - | - | - | 400 | 0 | - | - | - |
Share based compensation | |||||||||
21,105 | 19,774 | 26,874 | 29,102 | 25,900 | 15,900 | 5,444 | 22,410 | - | - |
Change in fair value of contingent consideration | |||||||||
-2,948 | 11,590 | 19,389 | - | - | 0 | 0 | - | - | - |
Deferred income tax | |||||||||
0 | 0 | -6,425 | -22,661 | -15,573 | -2,460 | 76 | - | - | - |
Legal accrual reversal | |||||||||
- | - | - | 2,967 | 0 | 0 | - | - | - | - |
Shares issued on behalf of related party | |||||||||
- | - | - | - | - | - | 81 | - | - | - |
Registration payment obligation expense | |||||||||
- | - | - | - | - | - | 360 | 0 | - | - |
Compensation in lieu of receivable | |||||||||
- | - | - | - | - | - | - | 407 | - | - |
Provision for income taxes | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Reversal of registration payment obligation liability | |||||||||
- | - | - | - | - | - | 360 | 0 | - | - |
Bargain purchase gain | |||||||||
- | - | - | - | 49,063 | 0 | 0 | - | - | - |
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | |||||||||
- | - | - | 18,383 | 13,778 | - | - | - | - | - |
Payments from change in fair value of contingent consideration | |||||||||
5,661 | 8,085 | 3,949 | 4,416 | 1,325 | 0 | - | - | - | - |
Fair Value Adjustment of Warrants | |||||||||
0 | 0 | 4,491 | -1,655 | 33,307 | 23,786 | 10,100 | 0 | - | - |
Foreign currency transaction gain | |||||||||
-112 | -464 | 1,081 | 0 | 0 | - | - | - | - | - |
Other | |||||||||
51 | 396 | 83 | -54 | -405 | - | - | - | - | - |
Share based payment - Technology license contingent fee | |||||||||
- | - | - | - | - | - | - | 1,550 | - | - |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | |||||||||
5,184 | -152 | -4,945 | 6,090 | 4,504 | 7,959 | 0 | 0 | - | - |
Inventory | |||||||||
1,958 | 2,773 | 1,706 | 568 | 1,174 | 282 | 0 | 0 | - | - |
Prepaid expenses and other current assets | |||||||||
7,931 | 1,358 | 2,702 | 2,447 | 966 | -237 | 1,349 | 14 | - | - |
Prepaid income taxes | |||||||||
-555 | -1,126 | -621 | -4,644 | 8,107 | 0 | 0 | - | - | - |
Technology license fees | |||||||||
- | - | - | - | - | - | - | -150 | - | - |
Fair value of services provided by related parties | |||||||||
- | - | - | - | - | - | - | - | 12 | 12 |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | 3,379 | 20,604 | 2,842 | 2,978 | - | - |
Accounts payable | |||||||||
9,255 | -2,708 | 2,060 | -2,916 | - | - | - | - | - | - |
Accrued expenses and other current liabilities | |||||||||
7,943 | 16,630 | 596 | 12,588 | - | - | - | - | - | - |
Expenses paid by related parties | |||||||||
- | - | - | - | - | - | - | - | 0 | 0 |
Net cash used in operating activities | |||||||||
-58,214 | -24,958 | 7,403 | -3,441 | -1,389 | -45,850 | -17,589 | -2,736 | -0 | -0 |
Cash Flows From Investing Activities: | |||||||||
Purchase of fixed assets | |||||||||
195 | 727 | 887 | 1,428 | 22 | 663 | 117 | 24 | - | - |
Cash paid for intangible assets | |||||||||
15,370 | 18,974 | 13,122 | 10,496 | 7,008 | 3,301 | 5,433 | - | - | - |
Investment - Equity | |||||||||
0 | 15,000 | 0 | 0 | 0 | 93 | 106 | - | - | - |
Proceeds from the sale/maturity of marketable securities | |||||||||
259,100 | 162,800 | 114,500 | 159,500 | 9,977 | 6,493 | 4,385 | - | - | - |
Purchase of marketable securities | |||||||||
223,712 | 331,345 | 102,415 | 184,111 | 198,530 | 10,149 | 4,124 | - | - | - |
Purchase of amortizable intangible asset | |||||||||
- | - | - | - | - | - | - | 1,168 | - | - |
Repayment of technology license liability | |||||||||
- | - | - | - | - | - | 1,300 | - | - | - |
Proceeds from securities sold, not yet purchased | |||||||||
- | - | - | - | - | 7,500 | 4,194 | - | - | - |
Securities sold, not yet purchased | |||||||||
- | - | - | - | - | 7,500 | 2,865 | - | - | - |
Proceeds from the maturity of notes receivable | |||||||||
0 | 0 | 47,500 | 47,500 | 0 | 0 | - | - | - | - |
Increase in restricted cash | |||||||||
- | - | - | - | - | - | 40 | - | - | - |
Cash received upon sale of assets, net | |||||||||
- | - | - | - | 148,411 | 0 | 0 | - | - | - |
Cash paid for investment | |||||||||
- | - | - | - | - | 400 | 0 | - | - | - |
Cash paid upon acquisition, net of cash acquired | |||||||||
- | - | - | 615 | 33,430 | 29,150 | 0 | - | - | - |
Cash received in merger transaction | |||||||||
- | - | - | - | - | - | - | 3 | - | - |
Payments made on behalf of affiliate | |||||||||
- | - | - | - | - | - | - | 137 | - | - |
Loans made to stockholder | |||||||||
- | - | - | - | - | - | - | 372 | - | - |
Net cash provided by (used in) investing activities | |||||||||
19,863 | -203,291 | 45,602 | 10,370 | -80,602 | -37,263 | -5,406 | -1,699 | - | - |
Cash Flows From Financing Activities: | |||||||||
Payment of acquisition-related contingent consideration | |||||||||
3,388 | 9,721 | 4,099 | 10,511 | 3,103 | 1,163 | 0 | - | - | - |
Proceeds from related parties | |||||||||
- | - | - | - | - | - | - | 10 | - | - |
Repayment of net amounts due to related parties | |||||||||
- | - | - | - | - | - | 13 | 33 | - | - |
Payment of other liability | |||||||||
0 | 1,000 | 852 | 1,000 | 2,000 | 500 | 0 | - | - | - |
Payment of guaranteed minimum royalty | |||||||||
2,084 | 2,000 | 2,000 | 2,000 | 2,000 | 0 | 0 | - | - | - |
Proceeds from Note Purchase Agreement | |||||||||
- | - | - | - | - | 42,924 | 0 | 930 | - | - |
Proceeds from Issuance of Warrants | |||||||||
0 | 5,305 | 3,645 | 6,005 | 4,475 | 8,398 | 0 | - | - | - |
Proceeds from exercise of stock options | |||||||||
1,618 | 10,588 | 8,087 | 4,016 | 6,818 | 0 | 0 | - | - | - |
Proceeds from issuance of 2025 convertible senior notes | |||||||||
0 | 276,000 | 0 | 0 | - | - | - | - | - | - |
Repayment of note payable - related party | |||||||||
- | - | - | - | - | - | 885 | 45 | - | - |
Investors' deposits | |||||||||
- | - | - | - | - | - | -100 | 100 | - | - |
Proceeds from credit agreement | |||||||||
- | - | - | - | - | 42,366 | 0 | - | - | - |
Repurchase of 2019 convertible senior notes including premium | |||||||||
0 | 40,203 | 0 | 0 | - | - | - | - | - | - |
Repayment of Manchester note payable | |||||||||
- | - | - | - | - | 31,283 | 0 | - | - | - |
Excess tax benefit (shortfall) related to stock compensation | |||||||||
- | - | - | - | 2,425 | 0 | 0 | - | - | - |
Proceeds received from issuance of common stock | |||||||||
- | - | - | - | 149,487 | 40,000 | 30,937 | 3,475 | - | - |
Payment of debt issuance and financing costs | |||||||||
0 | 8,820 | 0 | 0 | 9,500 | 3,165 | 0 | - | - | - |
Repayment of credit facility | |||||||||
- | - | - | - | 45,000 | 0 | 0 | - | - | - |
Purchase of treasury stock, at cost | |||||||||
- | - | - | - | - | 2,257 | 958 | - | - | - |
Other financing activities | |||||||||
1,777 | 1,714 | 664 | -359 | 0 | - | - | - | - | - |
Net cash used in financing activities | |||||||||
-2,077 | 231,863 | 5,445 | -3,849 | 101,602 | 95,320 | 28,981 | 4,437 | - | - |
Effect of exchange rate changes on cash | |||||||||
-9 | -135 | -58 | 117 | -10 | 0 | 0 | - | - | - |
Net change in cash and cash equivalents | |||||||||
-40,437 | 3,479 | 58,392 | 3,197 | 19,601 | 12,207 | 5,986 | 1 | - | - |
Supplemental Disclosure of Cash Flow Information: | |||||||||
Cash paid for interest | |||||||||
7,669 | 1,880 | 2,070 | 2,070 | 5,838 | 4,080 | 28 | 14 | - | - |
Cash paid for income taxes | |||||||||
656 | 218 | 7,172 | 7,933 | 9,610 | 5 | 0 | - | - | - |
Non-cash Investing and financing activities: | |||||||||
Short swing profit judgment offset with settlement expense accrual | |||||||||
- | - | - | 2,025 | 0 | 0 | - | - | - | - |
Reclassification of derivative liability to equity due to exercise of warrants | |||||||||
0 | 0 | 11,221 | 14,715 | 25,537 | 23,365 | 0 | - | - | - |
Accrued royalty in excess of minimum payable to the sellers of Thiola | |||||||||
15,815 | 14,572 | 13,247 | 11,206 | 8 | 0 | 0 | - | - | - |
Term extension of current Thiola agreement | |||||||||
0 | 0 | 5,885 | 0 | 0 | - | - | - | - | - |
Present value of contingent consideration payable upon acquisition related to L-UDCA | |||||||||
- | - | - | 25,000 | - | 12,800 | 0 | - | - | - |
Adoption of ASU 2017-11 - reclassification of derivative liability of warrants with down round provisions | |||||||||
0 | 15,710 | 0 | 0 | - | - | - | - | - | - |
Present value of contingent consideration payable | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Shares issued in connection with Cholbam acquisition | |||||||||
- | - | - | - | 16 | 0 | 0 | - | - | - |
Present value of guaranteed minimum royalty payable to sellers of Thiola | |||||||||
- | - | - | - | - | 11,850 | 0 | - | - | - |
Note payable entered into upon acquisition of Manchester Pharmaceuticals, LLC. | |||||||||
- | - | - | - | - | 31,283 | 0 | - | - | - |
Unrealized loss on securities sold, not yet purchased | |||||||||
- | - | - | - | - | - | -113 | - | - | - |
Adjustment to existing shareholders | |||||||||
- | - | - | - | - | - | 10 | - | - | - |
Purchase of Kyalin in exchange for future consideration | |||||||||
- | - | - | - | - | 1,000 | 2,635 | - | - | - |
Reclassification of due from related parties | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Technology license liability | |||||||||
- | - | - | - | - | - | - | 1,300 | - | - |
Affiliate receivable applied to security deposit | |||||||||
- | - | - | - | - | - | 138 | - | - | - |
Share based payment made to investors for inducement to participate in financing | |||||||||
- | - | - | - | - | - | 1,324 | - | - | - |
Offering expense liability | |||||||||
- | - | - | - | - | - | 747 | - | - | - |
Increase in basis of indefinite lived intangible assets acquired from Kyalin due to accrual of deferred tax liability | |||||||||
- | - | - | - | - | - | 2,525 | - | - | - |
Change in cash | |||||||||
- | - | - | - | - | - | - | - | -0 | -0 |